AR113874A1 - EZH2 INHIBITOR COMBINATION THERAPIES - Google Patents

EZH2 INHIBITOR COMBINATION THERAPIES

Info

Publication number
AR113874A1
AR113874A1 ARP180103277A ARP180103277A AR113874A1 AR 113874 A1 AR113874 A1 AR 113874A1 AR P180103277 A ARP180103277 A AR P180103277A AR P180103277 A ARP180103277 A AR P180103277A AR 113874 A1 AR113874 A1 AR 113874A1
Authority
AR
Argentina
Prior art keywords
combination therapies
ezh2 inhibitor
inhibitor combination
ezh2
treatment
Prior art date
Application number
ARP180103277A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR113874A1 publication Critical patent/AR113874A1/en

Links

Abstract

La presente se relaciona con terapias de combinación que comprenden un inhibidor EZH2 y un agente quimioterapéutico y composiciones farmacéuticas asociadas, métodos de tratamiento y usos farmacéuticos.The present relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent and associated pharmaceutical compositions, methods of treatment and pharmaceutical uses.

ARP180103277A 2017-11-14 2018-11-09 EZH2 INHIBITOR COMBINATION THERAPIES AR113874A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762585781P 2017-11-14 2017-11-14

Publications (1)

Publication Number Publication Date
AR113874A1 true AR113874A1 (en) 2020-06-24

Family

ID=71523245

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103277A AR113874A1 (en) 2017-11-14 2018-11-09 EZH2 INHIBITOR COMBINATION THERAPIES

Country Status (1)

Country Link
AR (1) AR113874A1 (en)

Similar Documents

Publication Publication Date Title
CL2018003588A1 (en) Use of myostatin inhibitors and combination therapies.
PH12020551397A1 (en) Cot modulators and methods of use thereof
CO2017001493A2 (en) Kits comprising tigit inhibitors and anticancer agents
MX2019003735A (en) Dilutable formulations of cannabinoids and processes for their preparation.
MX2019001125A (en) Macrocycle kinase inhibitors.
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
BR112016029041A8 (en) use of a glutaminase inhibitor, pharmaceutical composition and pharmaceutical kit
UY36703A (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF A POLINUCLEOTIDE ON A PLANT
EA201791095A1 (en) CANCER TREATMENT METHOD
UY36014A (en) ? DERIVED FROM PIRAZOL AMIDA, PHARMACEUTICAL COMPOSITION AND METHOD TO TREAT OR PREVENT AUTOIMMUNE, INFLAMMATORY, METABOLIC OR CANCEROSE DISEASES ?.
EP3808367A3 (en) Targeting aneurysm disease by modulating phagocytosis pathways
MX2017017124A (en) 6-amino-quinoline-3-carbonitrils as cot modulators.
BR112019003533A2 (en) combination therapy with glutaminase inhibitors
MX2021007899A (en) Selective il-6-trans-signalling inhibitor compositions.
BR112017019352A2 (en) corticosteroid-compressed topical compositions related applications
DOP2018000034A (en) COMBINATIONS OF AN OX40 ANTIBODY AND A TLR4 MODULATOR AND USES OF THE SAME
MX2017013137A (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors.
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
CR20190471A (en) Modulators of pcsk9 expression
UY37342A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
DOP2019000015A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
MY181719A (en) Fragrance and flavor compositions comprising neopentyl glycol diacetate
CO2020003134A2 (en) Modulators of enac expression
MX2020004731A (en) Ezh2 inhibitor combination therapies.

Legal Events

Date Code Title Description
FB Suspension of granting procedure